Who founded Precision BioSciences?

Precision BioSciences was founded by MATTHEW KANE, Jeff Smith, Derek Jantz.

Who are Precision BioSciences's investors?

Precision BioSciences's investors include age1, Agent Capital, Aliment Capital, Brace Pharma, F-Prime Capital, OCV Partners, OUP (Osage University Partners), Pontifax AgTech and 5 more.

How much funding has Precision BioSciences raised?

Precision BioSciences has disclosed $153.3M raised across 3 of its 5 known rounds.

Where is Precision BioSciences headquartered?

Precision BioSciences is headquartered in Durham, US.

Precision BioSciences

NASDAQ: DTIL

Durham, US · Delaware corporation · 13 known investors

Find your way into Precision BioSciences

Paths you didn't know you had: your email and LinkedIn already hold routes to the Precision BioSciences team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).

Biotech Deep Tech Healthtech

Founders & leadership

MATTHEW KANECo-founder

Jeff Smith Co-founderJeff Smith is a molecular biologist with approximately three decades of experience in protein engineering, including directed evolution and computational methods. He has held leadership roles managing scientific teams and holds multiple patents in the field.

Derek Jantz Co-founderDerek Jantz is a co-founder of Precision BioSciences who has led research teams in biotech environments and contributed to early development of gene editing technology as an academic scientist. He has overseen development of multiple gene-edited therapeutic programs, several of which have advanced to clinical trials.

TODD MELBY Chief Operating Officer2015–2018Todd Melby served as President of Leadership Edge, a leadership development organization, and has held senior operational leadership roles scaling companies across agriculture, gene therapy, and immuno-oncology sectors.

Michael Amoroso President & CEOAmoroso previously served as chief executive officer and board chairman at Abeona Therapeutics, which he joined as chief commercial and operating officer in 2020. Earlier in his career he was senior vice president and chief commercial officer at Kite Pharma, led the Americas oncology commercial business at Eisai US, and held global marketing and CAR T commercial roles at Celgene.

Board

ROBERT ADELMANBoard directorCo-founder and Emeritus Managing Partner at venBio Partners

BEN AUSPITZBoard director

Investors · 13

age1listed by age1San Francisco · $500K – $4M

How we know: age1's portfolio page · Not right? Tell us

Agent Capitallisted by Agent CapitalWaltham

How we know: Agent Capital's portfolio page · the VCSheet dataset · Not right? Tell us

Aliment Capitallisted by Aliment CapitalLos Angeles · $3M – $5M

How we know: the VCSheet dataset · Not right? Tell us

Brace Pharmalisted by Brace PharmaAtlanta

How we know: Brace Pharma's portfolio page · Not right? Tell us

F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10M

How we know: F-Prime Capital's portfolio page · Not right? Tell us

OCV Partnerslisted by OCV PartnersLos Angeles

How we know: OCV Partners's portfolio page · Not right? Tell us

OUP (Osage University Partners)listed by OUP (Osage University Partners)Bala Cynwyd · $1M – $20M

How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us

Pontifax AgTechlisted by Pontifax AgTechLos Angeles

RA Capitallisted by RA CapitalBoston

How we know: RA Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Ridgeback Capitallisted by Ridgeback CapitalNew York

How we know: Ridgeback Capital's portfolio page · Not right? Tell us

venBio Partnerslisted by venBio PartnersSan Franciscovia Robert Adelman · board

How we know: board seat on SEC Form D · the VCSheet dataset · Not right? Tell us

Vivo Capitallisted by Vivo CapitalPalo Alto · $10M – $50M

How we know: Vivo Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Korea Investment PartnersreportedSeoul · $3M – $10M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$153.3M disclosed across 3 of 5 rounds · 2015–2026

▶$39.5MraisedMar 2019 · 23 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Derek JantzExecutive Officer, Director
Matthew KaneExecutive Officer, Director
Robert AdelmanDirector
Shalini SharpDirector
Jeff SmithExecutive Officer
Abid AnsariExecutive Officer
Tony YaoDirector

Offering amount: $70M
Amount sold: $39.5M
First sale: Mar 2019
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$88.1MraisedJun 2018 · 40 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Derek JantzExecutive Officer, Director
Tony YaoDirector
Matthew KaneExecutive Officer, Director
Abid AnsariExecutive Officer
Jeff SmithExecutive Officer
Robert AdelmanDirector

Offering amount: $110M
Amount sold: $88.1M
First sale: May 2018
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$25.6MraisedMay 2015 · 11 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

JEFF SMITHExecutive Officer
ROBERT ADELMANDirector
DEREK JANTZExecutive Officer, Director
MATTHEW KANEExecutive Officer, Director
TODD MELBYExecutive Officer
BEN AUSPITZDirector

Offering amount: $25.6M
Amount sold: $25.6M
First sale: Apr 2015
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events

$784.5Mvaluation at IPOMar 2019 · $16.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Founder mafia

3 people who came through Precision BioSciences went on to found or lead other companies.

Derek JantzCo-founderFounded Tune Therapeutics Michael AmorosoPresident, Chief Executive OfficerFounded Abeona Therapeutics Matthew KleimanFounding Team MemberFounded Cumulus

Related companies · 2

Life BiosciencesLife Biosciences is a biopharmaceutical company developing therapies focused on aging and age-related diseases, working across gene therapy and neuroscience programs. It advances drug candidates from discovery through clinical development.

IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.

Companies working in the same space as Precision BioSciences.

In the news

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpacebiospace.com · Aug 2026

Precision BioSciences Raises $7.5M in Fundingfinsmes.com · Mar 2026

Frequently asked questions

What does Precision BioSciences do?: Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
Who founded Precision BioSciences?: Precision BioSciences was founded by MATTHEW KANE, Jeff Smith, Derek Jantz.
Who are Precision BioSciences's investors?: Precision BioSciences's investors include age1, Agent Capital, Aliment Capital, Brace Pharma, F-Prime Capital, OCV Partners, OUP (Osage University Partners), Pontifax AgTech and 5 more.
How much funding has Precision BioSciences raised?: Precision BioSciences has disclosed $153.3M raised across 3 of its 5 known rounds.
Where is Precision BioSciences headquartered?: Precision BioSciences is headquartered in Durham, US.